Neuroendocrine Prostate Cancer Market Report 2026

Neuroendocrine Prostate Cancer Market Overview

• Neuroendocrine Prostate Cancer market size has reached to $1.05 billion in 2025 • Expected to grow to $1.6 billion in 2030 at a compound annual growth rate (CAGR) of 8.7% • Growth Driver: Increasing Prevalence Of Prostate Cancer Driving The Market Growth Due To Rising Aging Male Population • Market Trend: Next-Generation Therapeutic Approaches Targeting Treatment-Resistant Tumors • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Neuroendocrine Prostate Cancer Market?

Neuroendocrine prostate cancer is a rare and aggressive form of prostate cancer characterized by the presence of neuroendocrine cells, which can influence tumor growth and resistance to conventional therapies. The disease may develop de novo or emerge following long-term androgen deprivation therapy in prostate cancer patients. Treatment approaches include chemotherapy, targeted therapy, immunotherapy, and supportive care to manage symptoms and improve patient outcomes. The main types of neuroendocrine prostate cancer include chemotherapy and hormonal therapy. Chemotherapy refers to the use of cytotoxic drugs to kill or inhibit the growth of cancer cells in the prostate. These treatments are also available as therapeutics including immunotherapy and targeted therapy. They are applied across disease stages including localized disease, advanced disease, and metastatic disease, and are used by end users including hospitals, oncology specialty clinics, and cancer research institutes.

What Is The Neuroendocrine Prostate Cancer Market Growth Forecast?

The neuroendocrine prostate cancer market size is expected to see strong growth in the next few years. It will grow to $1.6 billion in 2030 at a compound annual growth rate (CAGR) of 8.7%. The growth in the forecast period can be attributed to growth of precision oncology adoption, rising biomarker based treatment, expansion of targeted therapies, increased rare cancer research funding, broader genomic testing use. Major trends in the forecast period include biomarker driven patient stratification, combination oncology therapy protocols, advanced molecular diagnostic testing, rare cancer clinical trial expansion, targeted radiopharmaceutical approaches.

Global Neuroendocrine Prostate Cancer Market Segmentation

1) By Treatment: Chemotherapy; Hormonal Therapy 2) By Therapeutics: Immunotherapy; Targeted Therapy 3) By Disease Stage: Localized Disease; Advanced Disease; Metastatic Disease 4) By End Users: Hospitals; Oncology Specialty Clinics; Cancer Research Institutes Subsegments: 1) By Chemotherapy: Platinum Based Chemotherapy; Taxane Based Chemotherapy; Combination Chemotherapy; Second Line Chemotherapy 2) By Hormonal Therapy: Androgen Deprivation Therapy; Androgen Receptor Inhibition; Hormone Synthesis Inhibition; Combined Hormonal Therapy

What Is The Driver Of The Neuroendocrine Prostate Cancer Market?

The increasing prevalence of prostate cancer is expected to propel the growth of the neuroendocrine prostate cancer market going forward. Prostate cancer is a malignant tumor that develops in the prostate gland, primarily affecting men over the age of 50. The prevalence of prostate cancer is rising largely due to the growing aging male population, as advancing age is a major risk factor for disease development. Prevalence of prostate cancer supports the growth of neuroendocrine prostate cancer by expanding the overall patient pool, increasing long-term exposure to androgen-deprivation therapies, and consequently raising the likelihood of treatment-induced neuroendocrine differentiation in advanced and castration-resistant disease stages. For instance, in January 2025, the Centers for Disease Control and Prevention (CDC), a U.S. federal public health agency, reported that in 2023 there were 255,395 new cases of prostate cancer diagnosed in the United States, and 33,881 men died from the disease. Therefore, increasing prevalence of prostate cancer is driving the growth of the neuroendocrine prostate cancer industry.

Key Players In The Global Neuroendocrine Prostate Cancer Market

Major companies operating in the neuroendocrine prostate cancer market are Novartis AG, Amgen Inc., Phanes Therapeutics Inc., and BioXcel Therapeutics Inc.

Global Neuroendocrine Prostate Cancer Market Trends and Insights

Major companies operating in the neuroendocrine prostate cancer market are focusing on developing innovative drugs such as immune-modulating small-molecule therapies to enhance immune response and improve patient outcomes. Immune-modulating small-molecule therapies are orally administered compounds that stimulate the body’s innate immune system to recognize and attack cancer cells, helping overcome resistance to traditional treatments such as hormone therapy or chemotherapy by enhancing the anti-tumor immune response. For instance, in February 2024, BioXcel Therapeutics, a US-based clinical-stage biopharmaceutical company, received Fast Track Designation from the U.S. Food and Drug Administration for BXCL701, an immune-modulating small-molecule therapy for neuroendocrine prostate cancer. BXCL701 is designed to activate the NLRP3 inflammasome, increase cytokine release, and prime the immune system to target tumor cells, offering a novel approach that complements immune checkpoint inhibitors. The Fast Track Designation is expected to accelerate the clinical development and regulatory review of BXCL701, reflecting its potential to address significant unmet medical needs in aggressive and treatment-resistant prostate cancer.

What Are Latest Mergers And Acquisitions In The Neuroendocrine Prostate Cancer Market?

In March 2024, Merck & Co. Inc., a US-based healthcare and biopharmaceutical company, acquired Harpoon Therapeutics, Inc. for an undisclosed amount. With this acquisition, Merck & Co., Inc. aims to broaden and diversify its oncology pipeline by enhancing its portfolio of novel T-cell engagers for advanced cancers. Harpoon Therapeutics Inc. is a US-based biotechnology company that specializes in developing innovative T-cell engager therapies targeting cancers such as small cell lung cancer, neuroendocrine prostate cancer, and multiple myeloma.

Regional Insights

North America was the largest region in the neuroendocrine prostate cancer market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Neuroendocrine Prostate Cancer Market?

The neuroendocrine prostate cancer market consists of revenues earned by entities by providing services such as advanced diagnostic and pathological testing, molecular and biomarker analysis, oncological consultations, personalized treatment planning, and administration and monitoring of systemic therapies. The market value includes the value of related goods sold by the service provider or included within the service offering. The neuroendocrine prostate cancer market also includes sales of chemotherapeutic agents, hormone therapy–resistant drugs, radiopharmaceuticals, diagnostic kits and biomarker assays, and supportive oncology medications. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Neuroendocrine Prostate Cancer Market Report 2026?

The neuroendocrine prostate cancer market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the neuroendocrine prostate cancer industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.